NEW YORK, NY / ACCESSWIRE / March 16, 2018 / Alexion Pharmaceuticals saw a pop in its share price on Thursday after the company said its next-generation blood drug ALXN1210 held up well against its big money making drug Soliris in a key trial. Both drugs are indicated for the treatment of PNH, which is a rare disease that is characterized by destruction of red blood cells (hemolytic anemia), blood clots (thrombosis), and impaired bone marrow function. Flex Pharma also saw a dramatic increase in share price despite no big news.

RDI Initiates Coverage on:

Flex Pharma, Inc.
https://rdinvesting.com/news/?ticker=FLKS

Alexion Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=ALXN

Flex Pharma, Inc. shares exploded in Thursday trading, closing the day up 27.34% at $7.36 and seeing gains of roughly 3% in after-hours trading as well. The stock even hit a new 52-week high of $8.98 during intra-day trading. There was no particular news from the Boston-based biotech company to explain the gains. It was earlier in the month that Flex Pharma reported its earnings. It was last week that an analyst from Cantor Fitzgerald reiterated a "hold" rating on the company with a $6.00 price target. The analyst wrote, "Flex announced completion of enrollment in the exploratory Phase II study in MS spasticity, with topline results expected at the end of 1Q18. We think this could be a meaningful inflection point for the shares as it could reset the probability of success for FLX-787. Trials in ALS and Charcot-Marie-Tooth syndrome (CMT) are underway but for the indications of cramps as opposed to spasticity, the indication for the MS program."

Access RDI?s Flex Pharma, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FLKS

Alexion Pharmaceuticals, Inc. shares closed up 3.38% yesterday on about 11 million shares traded. The pharma stock saw gains after it was revealed that the company's next-generation blood disease drug called ALXN1210, did well next to its most lucrative drug in a key trial. The drug was proven to be not inferior to the company's Soliris drug in treating a rare disease called paroxysmal nocturnal hemoglobinuria (PNH). The drug was also found to be favored in six numeric goals. Geoffrey Porges, an analyst with Leerink, remarked in a note, "This data is consistent with our thesis that ALXN1210 will allow Alexion to extend the (intellectual property) of their complement franchise from the mid- to late-2020s to 2035 and this should also mitigate many of the competitive concerns related to other complement inhibitors in development." Traders were cheering on the news as Soliris is already approved for the treatment of PNH and makes up a big chunk of the company's sales.

Access RDI's Alexion Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ALXN

Our Actionable Research on Flex Pharma, Inc. (NASDAQ: FLKS) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com